Comparing pre-therapeutic (124)I and (131)I uptake tests with intra-therapeutic (131)I uptake in benign thyroid disorders.

Related Articles

Comparing pre-therapeutic (124)I and (131)I uptake tests with intra-therapeutic (131)I uptake in benign thyroid disorders.

Endocrine. 2017 Mar 07;:

Authors: Gühne F, Kühnel C, Freesmeyer M

Abstract
PURPOSE: (124)I-PET/CT can be used for pre-therapeutic assessment of radioactive iodine uptake in benign thyroid disorders, however systematic comparisons with intra-therapeutic uptake are still lacking for these disorders. The goals of this study were to compare (124)I RAIU and conventional (131)I RAIU tests with each other; to compare both tests with intra-therapeutic uptake (reference); and to verify the time course of radioactive iodine uptake at three time points (30, 102, and 336 h [14 days] post administration; p.a.).
METHODS: Thirteen patients with benign thyroid diseases underwent (131)I RAIU test and (124)I RAIU test one after another before the intra-therapeutic (131)I uptake (reference) was measured via short-range and long-range measurements. After correction for decay, relative uptake differences were calculated and subjected to the Bland-Altman method for the evaluation of levels of agreement.
RESULTS: Radioactive iodine uptake tests with (124)I-PET/CT and (131)I probe did not show systematic deviations at any time point. Likewise, at 30 and 102 h p.a. there was no systematic discrepancy between pre-therapeutic and intra-therapeutic uptake levels. At 14 days p.a., however, both pre-therapeutic tests tended to overestimate the uptake compared to reference. Findings showed, for the first time with (124)I, that radioiodine therapy has some early radiobiological effects possibly limiting the accuracy of pre-therapeutic dosimetry.
CONCLUSIONS: (124)I RAIU tests represent a feasible alternative to standard (131)I RAIU tests. The additional benefits of (124)I-PET/CT (e.g., functional topography, inclusion of retrosternal areas, possibility to enable fusion imaging) may thus increase the scope of this technology in benign thyroid disorders.

PMID: 28271395 [PubMed - as supplied by publisher]

http://ift.tt/2moH1Sj